Review ArticleAntibody-drug conjugates: an evolving approach for melanoma treatmentAnderson, Trevor S.a; Wooster, Amanda L.a; La-Beck, Ninh M.a,,b; Saha, Dipongkora; Lowe, Devin B.aAuthor Information Departments of aImmunotherapeutics and Biotechnology bPharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas, USA Received 18 August 2020 Accepted 7 October 2020 Correspondence to Devin B. Lowe, PhD, Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, 1718 Pine Street, Office 1306, Abilene, TX 79601, USA., Tel: +1 325 696 0486; e-mail: [email protected] Melanoma Research: February 2021 - Volume 31 - Issue 1 - p 1-17 doi: 10.1097/CMR.0000000000000702 Buy Metrics Abstract Melanoma continues to be an aggressive and deadly form of skin cancer while therapeutic options are continuously developing in an effort to provide long-term solutions for patients. Immunotherapeutic strategies incorporating antibody-drug conjugates (ADCs) have seen varied levels of success across tumor types and represent a promising approach for melanoma. This review will explore the successes of FDA-approved ADCs to date compared to the ongoing efforts of melanoma-targeting ADCs. The challenges and opportunities for future therapeutic development are also examined to distinguish how ADCs may better impact individuals with malignancies such as melanoma. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.